CAS: 1258595-14-0

LHC-165 is an agonist of TLR7. It also has the potential to treat solid tumors.

LHC-165 is a biodegradable polymer drug that targets the tumor microenvironment. LHC-165 has been shown to induce myeloid-derived suppressor cells (MDSCs) and inhibit TGF-β signaling. MDSCs are immunosuppressive cells that have been implicated in tumor progression and resistance to therapy, as well as in postoperative recurrence of cancer. The mechanism of action of LHC-165 is mediated by toll-like receptor 4 (TLR4) activation. This leads to an intratumoral accumulation of MDSCs and an intraoperative reduction in their number. In addition, LHC-165 has been shown to be effective for the treatment of colorectal cancer when used with resection or radiation therapy.